SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 75 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $15,000 | -21.1% | 2,048 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $19,000 | +72.7% | 2,048 | 0.0% | 0.00% | – |
| Q1 2019 | $11,000 | 0.0% | 2,048 | -16.3% | 0.00% | – |
| Q4 2018 | $11,000 | -94.2% | 2,448 | -91.0% | 0.00% | -100.0% |
| Q2 2018 | $191,000 | -48.1% | 27,232 | +5.3% | 0.01% | -53.8% |
| Q1 2018 | $368,000 | +62.1% | 25,872 | 0.0% | 0.01% | +62.5% |
| Q4 2017 | $227,000 | -32.4% | 25,872 | -10.0% | 0.01% | -33.3% |
| Q3 2017 | $336,000 | -10.6% | 28,736 | +6.7% | 0.01% | -14.3% |
| Q2 2017 | $376,000 | +68.6% | 26,928 | +65.8% | 0.01% | +55.6% |
| Q1 2017 | $223,000 | +92.2% | 16,240 | 0.0% | 0.01% | +80.0% |
| Q4 2016 | $116,000 | – | 16,240 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |